---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015441"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:59:30.019570+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx secures MHRA pathway for AAV-AIPL1 approval without further studies; Q3 net loss $39.3M

## Summary
- AAV-AIPL1 MAA under exceptional circumstances agreed with MHRA; no further clinical studies required for UK approval.
- 11 blind children treated with AAV-AIPL1 all gained vision within 4+ weeks; FDA discussions initiated for similar US pathway.
- AAV-GAD bridging study met safety endpoint; 18-point improvement in UPDRS Part 3 'off' score (p=0.03) at Week 26.
- Three FDA Rare Pediatric Disease Designations awarded for AIPL1, BBS10, and RDH12 programs.
- Cash $122.9M + $3.3M receivables; net loss $39.3M ($0.55 per share) vs $44.3M ($0.74) YoY.

## SEC filing metadata
- accession: 0001558370-24-015441
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837024015441/0001558370-24-015441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837024015441/mgtx-20241113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015441
- JSON: https://secwatch.observer/filing/0001558370-24-015441.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015441.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.